<DOC>
	<DOCNO>NCT00719563</DOCNO>
	<brief_summary>RATIONALE : American ginseng may reduce fatigue patient cancer . It yet know whether American ginseng effective placebo treat cancer-related fatigue . PURPOSE : This randomized phase III trial study American ginseng see well work treat patient fatigue caused cancer .</brief_summary>
	<brief_title>American Ginseng Treating Patients With Fatigue Caused Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy American ginseng ( Panax quinquefolius ) therapy cancer-related fatigue measure general subscale Multidimensional Fatigue Symptom Inventory-Short Form ( MFSI-SF ) . Secondary - To evaluate toxicity tolerability American ginseng use cancer-related fatigue . - To examine stress mediate variable effect American ginseng cancer-related fatigue . - To explore impact American ginseng various dimension fatigue measure subscales MFSI-SF , functional interference measure Brief Fatigue Inventory ( BFI ) , stress measure Perceived Stress Scale , well measure Profile Mood States ( POMS ) , well single measure fatigue . - To determine clinically significant change fatigue score use global impression change . - To evaluate whether difference efficacy American ginseng fatigue base minority population . Tertiary - To describe cortisol cytokine value fatigue cancer survivor evaluate relationship cortisol cytokine fatigue severity well pattern alteration previously document fatigue breast cancer survivor . - To evaluate whether Wisconsin Ginseng impact expression cortisol cytokine fatigue cancer survivor . - To evaluate role cortisol cytokine change mechanism Wisconsin Ginseng ameliorate cancer relate fatigue . - To evaluate relationship cytokine cortisol level secondary outcomes mood stress . OUTLINE : This multicenter study . Patients stratify accord baseline fatigue score ( 4-7 v 8-10 ) , disease status current cancer ( initial diagnosis v recurrent disease ) , current treatment ( chemotherapy , radiation , endocrine therapy [ i.e. , tamoxifen aromatase inhibitor ] , targeted therapy ) ( yes v ) , duration prior cancer treatment patient 's lifetime ( none v ≤ 180 day vs &gt; 180 day ) , current tumor type ( hematologic v solid tumor malignancy ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral American ginseng twice daily 14 day . Treatment repeat every 2 week 4 course disease progression unacceptable toxicity . - Arm II : Patients receive oral placebo twice daily 14 day . Treatment repeat every 2 week 4 course . Patients instruct complete Ginseng Symptom Experience Diary Linear Analogue Scale weekly . Patients also complete Multidimensional Fatigue Symptom Inventory-Short Form ( MFSI-SF ) , Profile Mood States ( POMS ) , Brief Fatigue Inventory ( BFI ) questionnaires baseline periodically study therapy . Patients actively receive chemotherapy radiation therapy undergo blood saliva sample collection baseline periodically study therapy correlative study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<criteria>1 . Required characteristic ≥ 18 year age Men woman history cancerrelated fatigue define average score ≥ 4 past 30 day numeric analogue scale ( 1 10 ) The presence fatigue ≥ 1 month prior randomization ECOG performance score 0 , 1 , 2 Histologic cytologic proven cancer brain cancer CNS lymphoma , undergo curative intent therapy ( include antihormonal therapy tamoxifen leuprolide ) complete curative intent therapy diagnose within past 2 year Note : If patient receive treatment disease chemotherapy , targeted therapy , immunotherapy radiation therapy , patient must complete ≥ 1 cycle chemotherapy , target therapy , ≥ 1 week radiation treatment . Laboratory value obtain prior randomization : Hgb ≥ 11 ( must obtain ≤ 30 day ; patient must transfuse ≤ 30 day meet criterion ) Creatinine ≤ 1.2 x UNL ( must obtain ≤ 180 day prior randomization ) AST ( SGOT ) ALT ( SGPT ) ≤ 1.5 x UNL ( must obtain ≤ 180 day prior randomization ) Negative pregnancy test do ≤ 7 day prior registration , woman childbearing potential Ability complete patient questionnaires alone assistance Controlled : Pain ( ≤ 4 Linear Analogue Scale ) Insomnia ( ≤ 4 Linear Analogue Scale ) Willingness provide blood/saliva sample correlative study . Note : These sample require receive active treatment disease . Active treatment define chemotherapy , radiation therapy , immunotherapy , antihormone therapy tamoxifen , aromatase inhibitor leuprolide . 2 . Contraindications Hypersensitivity ginseng Prior use ginseng capsule fatigue past year Note : Prior use teas drink contain ginseng allow , however , patient ask avoid beverage study . Uncontrolled hypertension one occasion ( diastolic blood pressure &gt; 100 , systolic &gt; 160 ) measure ≤ 90 day prior randomization Currently use pharmacologic agent nonpharmacologic intervention specifically treat fatigue include psychostimulants , antidepressant , acupuncture , etc . Note : Antidepressants use treat item fatigue ( hot flash ) allow patient stable dose ≥ 1 month plan continue ≥ 1 month . Erythropoietin agents treat anemia allow . Exercise allow . Known brain metastasis primary CNS malignancy Chronic systemic steroid use ( include CHOP therapy part regular cancer treatment , however , steroid use prophylaxis nausea vomit allow ) prevent rash Alimta , low dose dexamethasone allow . Diabetes Type I II ( define oral hypoglycemics insulin ) . Psychiatric disorder severe depression , manic depressive disorder , obsessive compulsive disorder schizophrenia . ( Defined per medical history ) . ≤ 4 week major surgery randomization , include procedure require general anesthetic Any following : Pregnant woman Nursing woman Women childbearing potential unwilling employ adequate contraception Pain require opioid pain medication , however , counter analgesic Tylenol ibuprofen allow . Use full dose anticoagulant therapy ( Exception : 1 mg/day Coumadin prevent catheter clot allow ) . Use MAO inhibitor . Planning start complete type cancer therapy 8 week , double blind , course study , randomize study . Note : If currently get treatment , chemotherapy agent ≤ 21 day prior randomization . Combination treatment regimens component end different time allow , long part initially start treatment continue double blind portion study . Malnutrition , active infection , significant pulmonary disease cardiovascular disease determine physician , could impact fatigue . Use counter herbal/dietary supplement market fatigue energy ( example , product contain type ginseng , rhodiola rosea , high dos caffeine , guarana , anything call `` adaptogen '' ) . Uncontrolled nausea vomit symptom would prevent ability comply daily oral ginseng/placebo treatment . Uncontrolled thyroid disorder . Currently receive single agent blind placebo control treatment trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>fatigue</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>